[go: up one dir, main page]

CO2023007677A2 - Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk - Google Patents

Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk

Info

Publication number
CO2023007677A2
CO2023007677A2 CONC2023/0007677A CO2023007677A CO2023007677A2 CO 2023007677 A2 CO2023007677 A2 CO 2023007677A2 CO 2023007677 A CO2023007677 A CO 2023007677A CO 2023007677 A2 CO2023007677 A2 CO 2023007677A2
Authority
CO
Colombia
Prior art keywords
pyrazolo
btk inhibitors
pyrazine derivatives
formula
pyrazine
Prior art date
Application number
CONC2023/0007677A
Other languages
English (en)
Inventor
Lopez De Turiso Felix Gonzalez
Andrew George Capacci
Martin Himmelbauer
Edward Yin Shiang Lin
Brian T Hopkins
Bin Ma
Isaac Marx
Jurgen Schulz
George Vandeveer
Robin Prince
Marta Nevalainen
Teyu Chen
Zain Yousaf
Vatee Pattaropong
John Howard Jones
Thomas Purgett
Simone Sciabola
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of CO2023007677A2 publication Critical patent/CO2023007677A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos de Fórmula (I'): (I'), o sales farmacéuticamente aceptables de los mismos, en donde las variables en la fórmula son como se definen en la presente y métodos para su uso y producción.
CONC2023/0007677A 2020-11-13 2023-06-13 Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk CO2023007677A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063113515P 2020-11-13 2020-11-13
PCT/US2021/059168 WO2022104079A1 (en) 2020-11-13 2021-11-12 Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors

Publications (1)

Publication Number Publication Date
CO2023007677A2 true CO2023007677A2 (es) 2023-09-08

Family

ID=78828007

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0007677A CO2023007677A2 (es) 2020-11-13 2023-06-13 Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk

Country Status (14)

Country Link
US (1) US20240083900A1 (es)
EP (1) EP4244223A1 (es)
JP (1) JP2023549360A (es)
KR (1) KR20230119134A (es)
CN (1) CN116783199A (es)
AR (1) AR124048A1 (es)
AU (1) AU2021377891A1 (es)
BR (1) BR112023009116A2 (es)
CL (1) CL2023001367A1 (es)
CO (1) CO2023007677A2 (es)
MX (1) MX2023005626A (es)
TW (1) TW202233624A (es)
UY (1) UY39517A (es)
WO (1) WO2022104079A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024544530A (ja) * 2021-11-12 2024-12-03 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤
CN119137114A (zh) 2022-05-04 2024-12-13 H.隆德贝克有限公司 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式
US20250304586A1 (en) * 2022-05-10 2025-10-02 Biogen Ma Inc. Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
WO2024117205A1 (ja) * 2022-11-30 2024-06-06 北興化学工業株式会社 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤
CN116693357A (zh) * 2023-06-07 2023-09-05 西安工程大学 一种β-三氟甲基不饱和酰胺及其合成方法
WO2025049254A1 (en) * 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
CN118955332A (zh) * 2024-07-31 2024-11-15 德阳悦合生物医药科技有限公司 一种作为医药中间体的化合物叔丁基甲基(3-酮环丁基)氨基甲酸酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610660B1 (en) * 1996-09-27 2003-08-26 The United States Of America As Represented By The Department Of Health And Human Services O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolates
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
AU2012323399A1 (en) * 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
WO2015017502A1 (en) * 2013-07-31 2015-02-05 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CN111285873B (zh) * 2018-12-07 2024-10-15 广东东阳光药业股份有限公司 Ret抑制剂、其药物组合物及其用途
EP3898626A1 (en) * 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases

Also Published As

Publication number Publication date
KR20230119134A (ko) 2023-08-16
US20240083900A1 (en) 2024-03-14
AR124048A1 (es) 2023-02-08
CL2023001367A1 (es) 2024-01-05
AU2021377891A1 (en) 2023-07-06
JP2023549360A (ja) 2023-11-24
UY39517A (es) 2022-06-30
CN116783199A (zh) 2023-09-19
AU2021377891A9 (en) 2024-04-18
TW202233624A (zh) 2022-09-01
BR112023009116A2 (pt) 2023-10-03
EP4244223A1 (en) 2023-09-20
WO2022104079A1 (en) 2022-05-19
MX2023005626A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
CO2023007677A2 (es) Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk
CO2022006858A2 (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
CO2021006114A2 (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
CU20210015A7 (es) COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
CL2024003196A1 (es) Heterociclos macrociclicos y usos de los mismos
AR050694A1 (es) Dihidropteridinonas para el tratamiento de enfermedades oncologicas
AR083751A1 (es) Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CL2022003007A1 (es) Compuestos de azalactama como inhibidores de hpk1
CL2025001257A1 (es) Proceso de elaboración de derivados de morfolinas sustituidas
MX2021000462A (es) Derivados de pirrolo-[1,2-b]-piridazina.
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
CL2024001873A1 (es) Sales y formas sólidas de un inhibidor de fgfr y procedimientos para su preparación.
UY28903A1 (es) Nuevos derivados de piridazinona
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
UY28738A1 (es) Deridos 1h-tieno(2,3-c)pirazol útiles como inhibidores de quinasa
MX2021010131A (es) Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.
CL2025000087A1 (es) Compuestos inhibidores de tirosina quinasa 2 y uso.
CO2021000782A2 (es) Agentes inhibidores de ask1
UY39475A (es) Compuestos útiles para la preparación de pirazolopirimidinonas
CL2025001386A1 (es) Compuestos derivados de hexahidropirano[3',4':4,5]pirrolo[2,3-d]pirimidina y uso para tratar cáncer.